Navigation Links
Quintiles Ranks First in Pan-European Clinical Investigator Study
Date:4/10/2008

World's leading pharma services company rated highest in overall

satisfaction

RESEARCH TRIANGLE PARK, N.C., April 10 /PRNewswire/ -- Quintiles Transnational Corp. today announced that an independently conducted study of clinical investigator sites across Europe placed Quintiles first in overall satisfaction. Quintiles also rated first in several other indicators of a clinical investigator's commitment to work with the world's leading pharmaceutical services provider.

Eighty-four percent of sites indicated that they were satisfied or extremely satisfied with their relationship with Quintiles.

The study, blinded and conducted by a third party, asked more than 300 European clinical investigators in 18 countries to rate their relationships and experience with Clinical Research Organizations (CROs). Investigators recruit patients and collect data for CROs and their pharmaceutical and biotechnology sponsors in studies that test drugs for safety and efficacy. Quintiles and eight other CROs were rated on 15 attributes by the investigator sites, including overall satisfaction, relationship building and allocation of resources for projects, including staff time.

"It is especially pleasing to see these results from all of our efforts to build strong relationships with investigators," said Lindy Jones, Vice President, Clinical Operations, Western Europe and Africa. "Because of our hard work, it is clear the sites are willing to devote more of their resources to projects they conduct with Quintiles than other CROs."

Clinical sites were asked to assign a percentage of resources -- such as time spent on patient recruitment -- that they had used on clinical studies with each CRO. Quintiles was allocated 38% of resources by the sites, with the nearest competitor being assigned only 13%, according to the survey. As for expected allocation of resources in the future, sites plan to continue giving additional resources to Quintiles projects at about a 3:1 ratio over other CROs.

"Allocation of resource is an important measure because it tells us where sites are more willing to put their limited time and effort," said Jones. "These results show that sites feel they get more return on their investment by working with Quintiles."

The relationship measurement was based on the question, "Which provider works hardest to develop a relationship with you/your site?" Quintiles was named by 49% of respondents. The closest competitor was named by only 10%.

Janos Filakovsky, Vice President and Managing Director, Eastern Region and Middle East, said, "Our continuing efforts to build strong relationships ultimately lead to more efficient use of time and resources, and that makes our customers happy. The end goal is more accurate feasibility, faster recruitment and safer patient management in clinical trials."

A third-party research company interviewed 308 investigators across Europe from January to February 2008. Investigators rated only those CROs with whom they had worked in the last 18 months. Respondents had an average of 13 years of experience in conducting clinical research, and sites had conducted an average of 11 studies over the last 18 months. For source data, please refer to http://www.quintiles.com/results .

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.quintiles.com.


'/>"/>
SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Quintiles Data Management Surpasses 300 EDC Trials
2. Quintiles Central Laboratory in India Receives CAP Certification
3. Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i
4. Quintiles Appoints John Goodacre as General Counsel
5. Quintiles Acquires Central American Research Organization
6. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
7. State Report Ranks LIJ as New Yorks Best Hospital for Angioplasty Survival
8. National Magazine Ranks Highmark Best Green Information Technology Company in the Nation
9. National Quality Report Ranks Regions Hospital Highest in Area
10. Rising Medical Solutions, Inc. Ranks Fifth on the Private Company Index (PCI) Top Growth Companies List
11. iCAD Ranks #1 in Mammography CAD User Satisfaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology: